^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Purinergic receptor P2Y12 inhibitor

    Related drugs:
    2d
    PANTHEON: Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone (clinicaltrials.gov)
    P3, N=2570, Not yet recruiting, Montreal Heart Institute
    New P3 trial
    |
    aspirin
    11d
    Effects of ginkgo diterpene lactone glucosamine combined with clopidogrel on hemodynamics, neurocytokines, and inflammatory responses in patients with cerebral infarction complicated by coronary heart disease. (PubMed, J Med Biochem)
    No significant difference was observed in the incidence of adverse reactions between the two groups (P>0.05). The combination of GM and CLO is more effective than CLO monotherapy in improving hemodynamics, enhancing neurological function, and mitigating inflammatory responses in patients with CI complicated by CHD.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • BDNF (Brain Derived Neurotrophic Factor) • CRP (C-reactive protein) • GFAP (Glial Fibrillary Acidic Protein)
    13d
    DOSE: Randomized Comparison of Radiation Exposure to Operators in Coronary Intervention Between Right Radial and Left DRA (clinicaltrials.gov)
    P=N/A, N=1010, Completed, Yonsei University | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Jul 2025 | Trial primary completion date: Dec 2025 --> Mar 2025
    Trial completion • Trial completion date • Trial primary completion date
    16d
    BEACON-AA: Apixaban With or Without Clopidogrel in Stroke Patients With Atrial Fibrillation and Cerebral Atherosclerosis (clinicaltrials.gov)
    P4, N=586, Not yet recruiting, Yonsei University
    New P4 trial
    21d
    Integrative analysis identified THBS1 as a key prognostic biomarker with therapeutic vulnerability in patients with laryngeal cancer. (PubMed, Transl Cancer Res)
    The oncogenic role of THBS1 and its therapeutic vulnerability were validated by in vitro experiments using human laryngeal cancer cell lines. Our study supports THBS1 as a potential prognostic predictor with therapeutic vulnerability for laryngeal cancer, warranting further clinical validation.
    Journal
    |
    THBS1 (Thrombospondin 1) • CLDN2 (Claudin 2)
    25d
    BIRDGE 2: The Bridging Antiplatelet Therapy With Cangrelor 2 Study (clinicaltrials.gov)
    P4, N=50, Not yet recruiting, University of Florida
    New P4 trial
    28d
    TAILOR BLEED: Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (clinicaltrials.gov)
    P4, N=90, Recruiting, University of Florida | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Jul 2025 --> Jan 2026
    Trial completion date • Trial primary completion date
    1m
    Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2) (clinicaltrials.gov)
    P4, N=40, Recruiting, University of Florida | Not yet recruiting --> Recruiting
    Enrollment open
    1m
    IMPACT: Do new blood-thinning treatments commenced after cardiac surgery keep By-Pass Grafts open longer ? (ACTRN12613001362785)
    P4, N=400, Terminated, Waikato District Health Board | Not yet recruiting --> Terminated
    Trial termination
    1m
    A Study to Evaluate the Efficiency and Safety of Dual Pathway Inhibition for Preventing Femoropopliteal Artery Restenosis in Repeated Endovascular Interventions: a Multi-center Prospective, Randomized, Open-Label, Blind Endpoint Trial (DIVERSE-RE-MT) (ChiCTR2500110275)
    P=N/A, N=400, Not yet recruiting, The First Affiliated Hospital of Naval Medical University; The First Affiliated Hospital of Naval Medical University
    New trial
    1m
    Effect of shortening clopidogrel withdrawal time before OPCABG on perioperative bleeding risk: a multicentre randomized controlled, open, non-inferior study (ChiCTR2500109866)
    P=N/A, N=1132, Not yet recruiting, Zhongshan hospital, Fudan University; Zhongshan hospital, Fudan University
    New trial
    1m
    Co-treatment of ticagrelor and anti-PD-1 immunotherapy in tumor-associated macrophages reduces pancreatic cancer cell growth and migration through the TGF-β1/Smad2 pathway. (PubMed, Biomed Pharmacother)
    The combination of ticagrelor and cemiplimab inhibited TGF-β1 release from TAMs and Smad2 phosphorylation in cancer cells. Our data suggest that co-treatment of ticagrelor and cemiplimab in TAMs inhibits pancreatic cancer cell growth and migration by suppressing the TGF-β1/Smad2 signaling pathway, providing an emerging strategy aimed at re-educating or depleting TAMs to enhance the efficacy of immunotherapy in pancreatic cancer.
    Journal
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    Libtayo (cemiplimab-rwlc)